Oral Cancer Awareness Month is observed every April, and it highlights the urgent need for early detection. According to the American Cancer Society, oral and oropharyngeal cancers still claim about one life every hour in ...
Apr 1, 2026
0
3
Expanding eligibility for full low-income subsidies (LIS) to include those with incomes between 135% and 150% of the federal poverty level (FPL) is associated with a reduction in cost-related medication nonadherence in Medicare ...
Apr 1, 2026
0
1
Anxiety, depression and post-traumatic stress disorder (PTSD) are among the most common mental health conditions for which Australians are prescribed medicinal cannabis.
Apr 1, 2026
0
1
As lung cancer screening identifies an estimated 1.6 million suspicious lung nodules each year in the U.S. alone, physicians face a challenge. Most peripheral pulmonary lesions are benign, yet the malignant minority represent ...
Apr 1, 2026
0
2
Allergies are usually associated with the immune system, genetics, and environmental factors. Increasingly, however, another element is appearing in this puzzle: the gut microbiota. A review of studies published in the International ...
Apr 1, 2026
0
1
In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers from Mass General Brigham ...
Apr 1, 2026
0
1
Leading international professional associations have issued a joint statement taking a clear stance on electroconvulsive therapy (ECT) and calling for a scientific and evidence-based presentation of the treatment. In doing ...
Apr 1, 2026
0
3
A new tool designed to support people with dementia when being discharged from mental health hospitals has been co-designed and evaluated by researchers at The University of Manchester. The SAFER-Dem intervention shows promise ...
Apr 1, 2026
0
2
Fewer people in the United States can reach hospital-based obstetric care within a reasonable drive than a decade ago, according to a new national study led by the Harvard Pilgrim Health Care Institute. The study found that ...
Apr 1, 2026
0
1
For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study published online March 28 in ...
Apr 1, 2026
0
1
